Drug-loadable（T-ACE Beads）for Hepatoma Embolization Therapy

Cancer of Liver Clinical Trial

Official title:

Hydrophilic Radiopaque Microsphere With Doxorubicin for Hepatoma Embolization Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03299036
• Other study ID #: B-BR-105-054
• Status: Completed
• Phase: N/A
• Start date: June 1, 2017
• Est. completion date: October 16, 2018

Study information

• Verified date: October 2018
• Source: National Cheng-Kung University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of Radiopaque Microsphere (T-ACE Beads with doxorubicin) interventional therapy for patients with liver cancer

Description:

The study will evaluate the safety and tolerability of Taiwan ACE Beads with doxorubicin used for chemoembolization for the treatment of unresectable hepatocellular carcinoma.

The investigators will study the overall response rates of lesions with Taiwan ACE Beads.

The procedure is similar with the other commercializing drug-eluting beads. At the target vessels, radiologists will inject doxorubicin with Taiwan ACE Beads instead of Gelfoam or PVA (polyvinyl alcohol). The end point of injection is also similar with conventional TACE.

Determine the complication rates, progression free survival (PFS) and overall survival (OS) following Taiwan ACE Beads embolization.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: October 16, 2018
• Est. primary completion date: October 16, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

Patients must meet all of the following inclusion criteria in order to be entered into the study:

A. Both genders of patients age 20 or older.

B. Patients diagnosed of liver cancer (MUST meet at least ONE of the following criteria:)

1. Diagnosed via tumor biopsy by Pathologists, and confirmed by on-service physician.

2. High risk patients (Viral hepatitis B or C or cirrhotics) with typical liver cancer image appeared on more than two radiographic examinations (Ultrasound, MRI, CT scan or Angiography).

3. High risk patients (Viral hepatitis B or C cirrhotics) with evidence of enlarging image of liver cancer via more than two follow-up records.

C. In intermediate stage by BCLC staging, tumor size under 8 centimeters, with liver function at Child-Pugh class = 8, and is either difficult to accept an operation or reluctant to accept any operation.

D. Disease can be treated by transarterial chemoembolization, and can be evaluated by Ultrasound, Magnetic resonance imaging (MRI), or computed tomography (CT).

E. Performance status ECOG 2 or less. Patient has a life expectancy of at least 3 months.

Exclusion Criteria:

If patients meet any of the following criteria they may not be entered into the study:

A. major branch of portal vein has been invaded already; extrahepatic metastasis or the the other malignant tumors.

B. Evidences of decompensation: Total Bilirubin>2, PT prolong>3 seconds, Child-Pugh class>8, refractory ascites, active bleeding, hepatic encephalopathy, and severe infection.

C. Tumor size (diameter) larger than 8 centimeters.

D. Not on dialysis with Creatinine >2.0 mg/dL.

E. Allergic to iodine or other injections.

F. Other main organ failure (Heart, Lung, or Kidney).

G. WBC<3000, or Platelet Count <50,000 mg/dL.

H. Performance status ECOG of 3 or more.

I. Pregnant women and breath feeding women.

J. Patients whose blood vessel are too difficult to do Taiwan ACE Beads procedure.

K. Prominent AV shunt.

L. Severe atherosclerosis.

M. Vasospasm or possible major vascular injury.

N. Arteriovenous shunt patients, diameter larger than the size of microsphere available.

O. Collateral vascular exists and may endanger non-targeted area during arterial chemoembolization.

P. Contraindications for doxorubicin.

Q. Numerous of tumors locate at different lobes, high risk of Hepatic insufficiency.

R. Unwilling to sign a written informed consent form.

S. Allergic to pharmaceutical excipients related to Microspheres.

Related Conditions & MeSH terms

• Cancer of Liver
• Carcinoma, Hepatocellular
• Liver Neoplasms

Intervention

Device:
• Taiwan ACE Beads with doxorubicin
Similar with commercializing drug-eluting beads, radiologist inject Taiwan ACE Beads with doxorubicin instead of Gelfoam or polyvinyl alcohol.

Locations

Country	Name	City	State
Taiwan	National Cheng Kung University Hospital	Tainan

Sponsors (3)

Lead Sponsor	Collaborator
National Cheng-Kung University Hospital	National Cheng Kung University, The Industrial Technology Research Institute

Country where clinical trial is conducted

Taiwan, 

References & Publications (2)

Liu YS, Lin XZ, Tsai HM, Tsai HW, Chen GC, Chen SF, Kang JW, Chou CM, Chen CY. Development of biodegradable radiopaque microsphere for arterial embolization-a pig study. World J Radiol. 2015 Aug 28;7(8):212-9. doi: 10.4329/wjr.v7.i8.212. — View Citation

Liu YS, Ou MC, Tsai YS, Lin XZ, Wang CK, Tsai HM, Chuang MT. Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma. Korean J Radiol. 2015 Jan-Feb;16(1):125-32. doi: 10.3348/kjr.2015.16.1.125. Epub 2015 Jan 9. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Patients Survival (Safety)	Survival rate will be evaluated since treatment day until the date of death or final observation.	An average of 12 weeks.
Primary	Tumor response in patients with hepatoma who received Taiwan ACE beads (TACE) microspheres embolization evaluated with mRECIST criteria	mRECIST criteria will be used to evaluate tumor response in patients with hepatoma who received Taiwan ACE beads (TACE) microspheres embolization.	Three months
Secondary	Serum Level of AFP	Collect Doxorubicin's blood concentration, 5 mL each time	An average of 12 weeks